The first Huberman-Attia Journal Club examines the scientific evidence for metformin as a geroprotective agent and the role of belief in physiological responses to drugs. The discussion critiques the 2014 Bannister study, which suggested a survival advantage for metformin users, against the more recent Keys study, which highlights significant confounding variables like medication use and baseline health status. While metformin remains a first-line treatment for type 2 diabetes, its broader longevity benefits remain unproven in humans. Additionally, the conversation explores a novel study on nicotine, demonstrating that belief about drug dosage can modulate brain activity in the thalamus and prefrontal cortex, even when the actual dose remains constant. This highlights the power of belief-based modulation in neurobiology and underscores the necessity of rigorous, randomized controlled trials to validate potential health interventions.
Sign in to continue reading, translating and more.
Continue
